By AIM · AIM Media House
Gunjan Aggarwal has been appointed Head of Data & Analytics at Averitas Pharma , the U.S. subsidiary of Grünenthal GmbH, announced in a LinkedIn post. Aggarwal has held senior roles in consulting and in-house analytics functions.
At Novartis , she was Executive Director of Data Capabilities & Marketing Data Solutions, responsible for commercial data platforms and marketing analytics frameworks. Her earlier career included work in predictive modeling, patient segmentation, and digital health strategy.
She has also published and presented on methods to integrate data into decision-making processes, particularly in commercial operations and healthcare marketing analytics.
Data and Analytics in Pain Management Averitas Pharma was established in the United States in 2018 following its acquisition by Grünenthal , a German pharmaceutical company with a long-standing focus on pain research. The company is responsible for the U.S.
commercialization of QUTENZA ®, an 8% capsaicin topical patch indicated for neuropathic pain conditions, including postherpetic neuralgia and diabetic peripheral neuropathy. The treatment is part of Grünenthal’s broader portfolio strategy to expand non-opioid options for chronic pain.
In addition to its current indications, Averitas has overseen late-stage clinical development of QUTENZA® for other neuropathic pain settings. Earlier this year, the company completed patient recruitment for a Phase III trial assessing the treatment in post-surgical neuropathic pain.
As in many therapeutic areas, advancing such programs requires not only clinical trial data but also real-world evidence and health economics analysis. These inputs help establish the value of therapies in discussions with regulators, payers, and providers.
Analytics plays a central role in connecting trial outcomes with broader measures of patient benefit.
Continue on AIM Media House